Cian Healthcare Ltd
Incorporated in 2003, Cian Healthcare Ltd is engaged in manufacturing and marketing of pharmaceutical products.[1]
- Market Cap ₹ 18.1 Cr.
- Current Price ₹ 7.23
- High / Low ₹ 7.23 / 2.97
- Stock P/E
- Book Value ₹ 15.8
- Dividend Yield 0.00 %
- ROCE 5.22 %
- ROE 0.43 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.46 times its book value
- Company's working capital requirements have reduced from 35.1 days to 26.3 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 27.1%
- Company has a low return on equity of -1.91% over last 3 years.
- Promoters have pledged or encumbered 34.5% of their holding.
- Promoter holding has decreased over last 3 years: -39.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 57.09 | 73.73 | 77.87 | 68.59 | 61.70 | |
| 49.74 | 61.74 | 73.52 | 55.60 | 51.30 | |
| Operating Profit | 7.35 | 11.99 | 4.35 | 12.99 | 10.40 |
| OPM % | 12.87% | 16.26% | 5.59% | 18.94% | 16.86% |
| 0.79 | 0.07 | 0.47 | 0.73 | 1.12 | |
| Interest | 7.22 | 7.92 | 6.55 | 6.30 | 6.00 |
| Depreciation | 4.45 | 3.45 | 4.27 | 5.43 | 5.47 |
| Profit before tax | -3.53 | 0.69 | -6.00 | 1.99 | 0.05 |
| Tax % | 7.37% | 91.30% | -7.83% | -2.01% | -400.00% |
| -3.79 | 0.05 | -5.53 | 2.03 | 0.25 | |
| EPS in Rs | -1.62 | 0.02 | -2.21 | 0.81 | 0.10 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| TTM: | 27% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 53% |
| TTM: | -8600% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -10% |
| 3 Years: | -24% |
| 1 Year: | 65% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | 23.36 | 23.36 | 25.00 | 25.00 | 25.00 |
| Reserves | 34.83 | 34.88 | 30.46 | 32.49 | 32.74 |
| 72.94 | 70.73 | 63.05 | 60.81 | 55.69 | |
| 25.41 | 28.28 | 47.42 | 42.18 | 47.74 | |
| Total Liabilities | 156.54 | 157.25 | 165.93 | 160.48 | 161.17 |
| 39.43 | 36.54 | 49.58 | 44.59 | 39.28 | |
| CWIP | 25.03 | 25.93 | 13.00 | 13.89 | 14.70 |
| Investments | 4.89 | 4.89 | 4.89 | 4.89 | 4.89 |
| 87.19 | 89.89 | 98.46 | 97.11 | 102.30 | |
| Total Assets | 156.54 | 157.25 | 165.93 | 160.48 | 161.17 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| -7.31 | 5.93 | 8.58 | 4.84 | 11.76 | |
| -27.44 | 2.71 | 1.40 | 2.55 | -1.46 | |
| 35.78 | -9.78 | -10.96 | -7.41 | -10.44 | |
| Net Cash Flow | 1.03 | -1.13 | -0.98 | -0.01 | -0.14 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 127.80 | 93.56 | 125.24 | 139.58 | 121.15 |
| Inventory Days | 267.18 | 312.78 | 299.94 | 399.93 | 485.99 |
| Days Payable | 220.03 | 209.37 | 270.46 | 295.80 | 371.29 |
| Cash Conversion Cycle | 174.95 | 196.98 | 154.73 | 243.71 | 235.85 |
| Working Capital Days | 14.77 | 16.14 | 38.30 | 40.66 | 26.27 |
| ROCE % | 6.78% | 0.50% | 6.91% | 5.22% |
Documents
Announcements
-
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors
17 Oct - 15th CoC met Oct 17; to vote on Pradeep Kumar Jain's resolution-plan amendments; NCLT hearing Nov 6, 2025.
-
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors
15 Oct - Cian Healthcare under CIRP: 15th CoC meeting scheduled Oct 17, 2025 at 10:45 AM in Pune.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Oct - Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for quarter ended on September 30, 2025.
-
Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP)
7 Oct - NCLT heard CIRP today; next hearing for resolution plan on November 06, 2025.
-
Closure of Trading Window
26 Sep - Trading window closed Oct 1, 2025 until 48 hours after unaudited H1 results for Sep 30, 2025.
Business Overview:[1][2]
CHI is a fully integrated pharmaceutical company dealing in gynecology, hematinic, cardio-diabetic, orthopedic, pediatric, derma-cosmetic, antibiotic, CNS, vitamins & nutrient products.